GR agonists(Glucocorticoid receptor agonists), M1 receptor antagonists(Muscarinic acetylcholine receptor M1 antagonists), M2 receptor antagonists(Muscarinic acetylcholine receptor M2 antagonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesRespiratory Diseases

Active Indication

AsthmaBronchitis, ChronicPulmonary Disease, Chronic Obstructive+ [1]

Inactive Indication

Cardiovascular DiseasesCoronary DiseaseHypertension+ [4]

Originator Organization

GSK Plc

Active Organization

GlaxoSmithKline, Inc.GlaxoSmithKline Intellectual Property Development Ltd.

GSK Plc

+ [3]

Inactive Organization

Glaxo Group Ltd.

GlaxoSmithKline (China) Investment Co., Ltd.

License Organization

Royalty Pharma Plc

GSK Plc

Theravance Biopharma, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (18 Sep 2017),

Pulmonary Disease, Chronic Obstructive

RegulationSpecial Review Project (China)

Structure/Sequence

Molecular FormulaC44H49Cl2NO7

InChIKeyKLOLZALDXGTNQE-JIDHJSLPSA-N

CAS Registry503070-58-4

View All Structures (3)

Clinical Trials associated with Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate

NCT06905483

/ RecruitingPhase 4IIT

Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

The goal of this clinical trial is to determine if triple inhaled therapy with Budesonide/Glycopyrronium/Formoterol (BGF) and Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) are effective in treating patients with stable chronic obstructive pulmonary disease (COPD). It will also assess the safety of both drugs.
The main questions it aims to answer are:
* Does BGF demonstrate a comparable effect to FUV in COPD participants?
* What medical problems do participants experience when taking BGFand FUV?

Start Date01 Apr 2025

Sponsor / Collaborator

Thammasat University

NCT06474039

/ RecruitingPhase 3IIT

The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD

This study aims to demonstrate the effects of triple therapy (ICS/LABA/LAMA) and dual bronchodilators (LAMA/LABA) on air trapping in the lungs' COPD patients and inflammatory mediators

Start Date01 Oct 2024

Sponsor / Collaborator

Mahidol University

NCT06372496

/ Active, not recruitingPhase 4

A Phase 4, 52-week (Primary Analysis at 24-weeks), Randomized, Stratified, Open-label, Active-controlled, Parallel-group, Effectiveness Study, Comparing FF/UMEC/VI With Non-ellipta Usual Care (ICS/LABA) in Adult Participants With Uncontrolled Asthma

The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma

Start Date16 Apr 2024

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate

100 Translational Medicine associated with Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate

100 Patents (Medical) associated with Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate

Literatures (Medical) associated with Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate

01 Jul 2025·Respiratory Investigation

Analysis of adherence to ICS/LAMA/LABA in patients with asthma: a retrospective observational cohort study using medical claims data

Article

Author: Yarita, Masao ; Oga, Toru ; Ito, Risako ; Mukai, Isao ; Requena, Gema ; Mita, Chifuku ; Takano, Masashi

BACKGROUND:

Real-world evidence of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) use in Japan is limited. This real-world study assessed adherence to FF/UMEC/VI once-daily single-inhaler triple therapy (SITT) versus multiple-inhaler triple therapy (MITT) among patients with asthma in Japan.

METHODS:

Retrospective observational cohort study of patients with asthma initiating FF/UMEC/VI SITT or MITT, using claims data (02/18/2021-02/28/2022, JMDC database). Patients were aged ≥15 years at index (date of FF/UMEC/VI or MITT claim). Outcomes were assessed in two cohorts and weighted using inverse probability of treatment weighting: 1) 'overall cohort' included patients who received FF/UMEC/VI or MITT as initial maintenance therapy (IMT) or as non-IMT (i.e., had previously received inhaled corticosteroid-containing medication during baseline); 2) 'non-IMT cohort' was a sub-cohort of the overall cohort.

PRIMARY OUTCOME:

proportion of adherent patients (proportion of days covered ≥0.8) in the 3, 6, and 12 months after, and including, index date.

RESULTS:

The overall cohort comprised 7228 (FF/UMEC/VI) and 864 (MITT) patients. Of these, 3623 and 735 were included in the FF/UMEC/VI and MITT non-IMT cohort, respectively. At 3 months post-index, a significantly higher proportion of patients were adherent to FF/UMEC/VI (36.4 % [n = 2631]) versus MITT (31.2 % [n = 270]) in the overall cohort (rate ratio [95 % confidence interval], 1.16 [1.05-1.29], p = 0.003, weighted), and FF/UMEC/VI (36.6 % [n = 1326]) versus MITT (28.9 % [n = 213]) in the non-IMT cohort (1.26 [1.12-1.43], p < 0.001). Similar results were observed at 6, and 12 months post-index.

CONCLUSIONS:

Patients with asthma in Japan who initiated FF/UMEC/VI SITT had significantly better treatment adherence than those who initiated MITT.

01 Mar 2025·Pulmonary Therapy

Retrospective Cohort Study of Elderly Users of Single- or Multiple-Inhaler Triple Therapy for the Treatment of Asthma in the USA

Article

Author: Laliberté, Francois ; Paczkowski, Rosirene ; Burrows, Emmeline ; Duh, Mei Sheng ; Mahendran, Malena ; Settipane, Russell A ; Germain, Guillaume ; Hilts, Annalise

INTRODUCTION:

Escalation to single- or multiple-inhaler triple therapy (SITT; MITT) is a recommended option for patients with asthma who remain uncontrolled by medium-dose inhaled corticosteroid/long-acting β₂-agonist; however, characterization of elderly users of triple therapy is limited. This real-world cohort study describes demographics and clinical characteristics of elderly patients with asthma with and without comorbid chronic obstructive pulmonary disease (COPD) who are new users of triple therapy, and asthma treatment patterns preceding triple therapy initiation.

METHODS:

This retrospective cohort study used administrative claims data from the Optum Clinformatics Data Mart database. Eligible patients were ≥ 65 years of age with asthma or with asthma and comorbid COPD who initiated either triple therapy with single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; 100/62.5/25 μg) or MITT between September 18, 2017 and September 30, 2020. Demographics, clinical characteristics, healthcare resource utilization, healthcare costs, and asthma treatment patterns were described in the 12-month period before triple therapy initiation (baseline period).

RESULTS:

In total, 15,557 patients were included. Among FF/UMEC/VI initiators with asthma (N = 635) mean age was 73.3 years and 66.6% were female. During the baseline period, > 75% of patients used controller therapy, > 92% used rescue medications, 27.9% experienced ≥ 1 asthma-related exacerbation, with mean annual exacerbation rate of 0.42, and mean all-cause healthcare costs were $23,407. Patients with asthma initiating MITT and patients with asthma and comorbid COPD initiating FF/UMEC/VI or MITT had similar characteristics, healthcare resource utilization, healthcare costs, and asthma treatment patterns to FF/UMEC/VI initiators with asthma.

CONCLUSIONS:

Triple therapy is often initiated following use of other asthma controller medications in real-world practice. Substantial rescue medication use and high disease and economic burden among this elderly patient population suggest that their asthma was not adequately controlled prior to triple therapy initiation. This retrospective study provides an early profile of elderly patients with asthma in the USA.

01 Feb 2025·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Effect of non-spherical shape of dry powder aerosol drugs on their airway deposition distribution

Article

Author: Farkas, Á ; Nagy, A ; Ambrus, R ; Kolonits, T ; Kugler, Sz ; Füri, P ; Horváth, A ; Kheirandish, S

In the majority of aerosol drug deposition modelling efforts, the particles are approximated by regular spheres. However, microscope images acquired after drug formulation available in the open literature suggest that their shape is not regular in most of the cases. This work aimed to combine experimental measurements and numerical simulations to reveal the shape factors of the particles of commercialized aerosol drugs and the effect of non-sphericity on the lung deposition distribution of these drugs. Aerosol particles of Bretaris® Genuair®, Buventol® Easyhaler® and Trelegy® Ellipta® were collected on the stages of a Next Generation Impactor after their emission from the dry powder inhalers. The samples were analyzed using scanning electron microscopy techniques. Aspect ratios and dynamic shape factors characteristic of particles in the size fractions representing each impactor stage were determined. Computer modelling of their airway deposition was performed by both neglecting and considering their irregular shape. The results of particle size measurements revealed that there was no size-specific shape factor of the particles, as they could be well characterized by a global shape factor. Although there was some inter-drug difference in terms of shape factors, the values were quite close to unity (usually between 1.02 and 1.06), except for the fiber-shaped particles representing a minority in the composition of Trelegy® Ellipta®, which could be characterized by shape factors of around 1.6. The results of computer simulations of deposition distribution indicate that neglecting the irregular shape does not lead to a major distortion of the simulation results unless fiber-shaped particles are also present after the formulation.

News (Medical) associated with Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate

30 Jul 2025

·www.biospace.com

GSK to Inject ‘Tens of Billions’ in US Amid Trump’s Tariffs, Pipeline Reshuffles

iStock, Magdalena Wygralak CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for the country are supplied domestically. GSK will make a multi-billion-dollar investment in the U.S. in the coming years as the Trump administration’s tariffs materialize. “The U.S. is our number one priority market,” CEO Emma Walmsley told reporters on a media call Wednesday morning, while presenting the company’s second-quarter earnings report . “It’s in our plans to invest tens of billions [of] dollars in the U.S. over the next five years.” Walmsley did not reveal exactly how much money the company expects to spend, where it will go or what it will be used for. GSK continues to expand its footprint in the U.S., according to Walmsley, who noted that the pharma currently has five factories in the country and broke ground on a new manufacturing facility last quarter. GSK continues “to prioritize investments so that our portfolio in the U.S. is more and more supplied from the U.S,” she said. Walmsley’s statements come after the U.S. and the European Union arrived at a trade deal earlier this week, which adds a 15% tariff on pharmaceutical imports. Analysts expect these levies to cost the industry as much as $19 billion. GSK also reported on Wednesday a series of discontinuations in its pipeline. It is no longer investing in the anti-TIGIT antibody belrestotug, which it was developing alongside iTeos Therapeutics. The pharma in May broke off its engagement with the Massachusetts-based biotech following disappointing Phase II data in non-small cell lung cancer and head and neck cancer. GSK also revealed that it is pulling the plug on the antifungal agent ibrexafungerp, which it was advancing for invasive candidiasis in partnership with Scynexis. The FDA in September 2023 placed the Phase III MARIO study of ibrexafungerp in this indication under clinical hold due to a contamination issue. Scynexis revealed during its Q1 report in May that the hold had been lifted , but that GSK nevertheless wanted to terminate the study. GSK is also discontinuing the mid-stage vaccines GSK3437949 for malaria, GSK3536852 for shigella and GV118819 for tuberculosis. The pharma is also ending work on the Phase I vaccine GSK3536867 for salmonella. uygftv In the second quarter, GSK brought in £7.986 billion ($10.67 billion), representing a 6% year-on-year increase at constant exchange rates. Much of its growth was driven by its specialty medicines division, which jumped 15% to hit £3.327 billion ($4.45 billion) in the quarter. GSK’s vaccines business, earning £2.091 billion ($2.8 billion) in Q2, also delivered positive year-on-year growth. Some of GSK’s standout assets in Q2 include the asthma drug Trelegy Ellipta, which brought in £642 million ($858 million) in worldwide sales, and the lupus therapy Benlysta, which earned £372 million ($497 million). The pharma’s shingles vaccine Shingrix delivered £241 million ($322 million). Encouraged by what Walmsley called the company’s “strong momentum,” GSK raised its full-year turnover outlook. The pharma now expects to see growth toward the top end of its prior guidance, which is an increase of 3% to 5%.

VaccinePhase 2Phase 3Phase 1Clinical Result

24 Jun 2025

·www.prnewswire.com

Pulmonary Drug Delivery System Market Size to Worth USD 73.14 Billion by 2031 | The Insight Partners

NEW YORK, June 24, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global pulmonary drug delivery system market is observing significant growth owing to the increasing prevalence of chronic respiratory diseases and growing technological advancements in drug delivery. The pulmonary drug delivery system market is expected to reach US$ 73.14 billion by 2031 from US$ 54.14 billion in 2024, registering a CAGR of 4.4% during the forecast period. Pulmonary drug delivery is a targeted system that directs medications specifically to the lower respiratory tract. This system utilizes devices designed to administer drugs through the pulmonary route. Inhalation is an effective method for delivering treatments for asthma, chronic obstructive pulmonary disease (COPD), and other conditions. This approach offers rapid action, providing quick relief during asthmatic attacks and acute bronchitis. Aerosols are specially designed devices commonly used for pulmonary drug delivery. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the pulmonary drug delivery system market comprises a vast array of products and services that are expected to register strength during the forecast period. To explore the valuable insights in the Pulmonary Drug Delivery System Market report, you can easily download a sample PDF of the report - Overview of Report Findings Increasing Burden of Chronic Respiratory Diseases: As per the World Health Organization, the prevalence of asthma is increasing, with a projected growth of more than 100 million additional cases by 2025. Asthma is a chronic respiratory disease characterized by inflammation and narrowing of the airways. It is one of the major non-communicable diseases worldwide, affecting over 300 million individuals. The prevalence of asthma continues to increase each year, particularly in low and middle-income countries. According to the article published in the National Library of Medicine, in 2020, the global prevalence of COPD was estimated at 10.6%, resulting in ~480 million cases among both males and females. By 2050, the number of COPD cases is projected to rise by 112 million, reaching a total of 592 million, which would represent 9.5% of the total eligible population. This indicates a relative increase of 23.3% in COPD cases from 2020 to 2050. The increasing global burden of asthma, COPD, and cystic fibrosis is a significant factor driving the market for pulmonary drug delivery systems. Inhalers, nebulizers, and other pulmonary devices provide targeted administration of medications directly to the lungs, thereby enhancing treatment outcomes and patient adherence. This trend is fostering the global adoption of advanced pulmonary drug delivery systems. Surging Technological Advancements in Drug Delivery Systems: Ongoing advancements in drug delivery technologies, such as smart inhalers, metered-dose inhalers (MDIs), and dry powder inhalers (DPIs), are significantly transforming the pulmonary drug delivery market. The development of more efficient, precise, and user-friendly devices improves patient adherence and ensures better targeting of medications. In June 2024, Aseptika launched the PUFFClicker3, a universal smart inhaler dose tracker designed to be compatible with both pressurized metered dose inhalers (pMDI) and DPIs. The PUFFClicker3 aims to enhance inhaler adherence for patients of all ages and those with respiratory conditions that require inhalers for treatment. It supports 101 SNOMED-coded inhalers and includes built-in graphical instructions, making it easy to transition to a new type of inhaler. Such developments in the market make treatments for chronic respiratory diseases more effective and convenient for patients. Geographical Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and APAC. Asia Pacific is expected to register the highest CAGR during the forecast period. Stay Updated on The Latest Pulmonary Drug Delivery System Market Trends: Market Segmentation Based on product, the pulmonary drug delivery system market is segmented into dry powder inhalers, metered dose inhalers, and nebulizers. The dry powder inhalers segment held the largest share of the pulmonary drug delivery system market in 2024. In terms of application, the pulmonary drug delivery system market is categorized into cystic fibrosis, asthma, allergic rhinitis, COPD, and other applications. The cystic fibrosis segment held the largest share of the pulmonary drug delivery system market in 2024. In terms of end user, the pulmonary drug delivery system market is divided into hospitals, diagnostic centers, and other end users. The hospitals segment held the largest share of the pulmonary drug delivery system market in 2024. The pulmonary drug delivery system market is segmented into five major regions: North America, Europe, APAC, Middle East and Africa, and South and Central America. Competitive Strategy and Development Key Players: A few major companies operating in the pulmonary drug delivery system market are GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, Merck & Co., Pfizer, Teva Pharmaceutical Industries, Mylan N.V., Hovione, and Vectura Group. Trending Topics: Advanced Pulmonary Drug Delivery Systems, AI in Pulmonary Drug Delivery Systems, Drug Delivery Systems for COPD, and Increasing Asthma Prevalence, among others. Global Headlines on Pulmonary Drug Delivery System Aseptika launched the PUFFClicker3, a universal smart inhaler dose tracker that is compatible with both pMDI and DPI. The PUFFClicker3 supports 101 SNOMED-coded inhalers and includes built-in graphical instructions, making it easy for users to switch to a new inhaler type. Glenmark Pharma launched the Tiotropium Bromide Dry Powder Inhaler, branded as Tiogiva, for the treatment of COPD in the UK. PARI Pharma GmbH has received market authorization for the LAMIRA Nebulizer System, which delivers Insmed's drug product ARIKAYCE (amikacin liposome inhalation suspension) in Japan. GlaxoSmithKline Pharmaceuticals introduced Trelegy Ellipta, a once-daily single-inhaler triple therapy (SITT) for patients suffering from chronic obstructive pulmonary diseases in India. Conclusion The mounting incidence of chronic respiratory diseases, such as asthma and COPD, and increasing technological developments in drug delivery systems drive the pulmonary drug delivery system market growth. Chronic conditions are becoming more common, affecting millions of individuals across the world. According to the WHO, over 400 million people globally have asthma, highlighting the urgent need for innovative treatment options to ensure effective disease management. Additionally, the growing recognition of asthma and COPD as major public health challenges has encouraged the development and accessibility of advanced pulmonary drug delivery systems, contributing to market expansion. Technological innovation is crucial to the growth of the pulmonary drug delivery systems market. pMDIs, DPIs, soft mist inhalers (SMIs), and nebulizers, including vibrating mesh nebulizers, are advanced inhaler technologies that have enhanced drug delivery efficiency, improved patient compliance and yielded better therapeutic outcomes. These modern devices offer precise dosing, ease of use, portability, and increased drug deposition in the lungs. The report from The Insight Partners, therefore, provides several stakeholders—including pharmaceutical companies, academic and research organizations, healthcare facilities, and others—with valuable insights to successfully navigate this evolving market landscape and unlock new opportunities. Purchase Premium Copy of Global Pulmonary Drug Delivery System Market Size and Growth Report (2021-2031) at: Trending Related Reports: About Us: The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit Mathur E-mail: [email protected] Phone: +1-646-491-9876 Home - Logo: SOURCE The Insight Partners WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

02 Jun 2025

·www.fiercepharma.com

Theravance hands off the last of its Trelegy royalties to GSK for $225M

The royalty exchange with GSK comes after Theravance sold the majority of its Trelegy interest to Royalty Pharma in 2022. After years of picking up royalties on GSK’s asthma and COPD inhaler Trelegy, Theravance Biopharma is opting to sell its remaining financial interest to GSK in exchange for a cash reward of $225 million.With that, Theravance expects its lifetime value from the inhaler to come out to $1.52 billion. The drug stems from a 2002 collaboration between GSK and Theravance, in which Theravance handed over its long-acting beta agonist assets in exchange for royalties and milestone payments.The new one-time cash infusion from GSK was in the interest of churning out “immediate value” for shareholders, CEO Rick Winningham said in a June 2 release, marking the first outcome of the ongoing efforts of a strategic review committee brought together in 2024 to hunt for strategic alternatives. It comes after the company offloaded the majority of its Trelegy royalty rights to Royalty Pharma in 2022 for an upfront payment of some $1.31 billion, with up to $150 million more to come in 2025 and 2026 if the inhaler meets certain sales goals. Thervance still has the right to bring in 85% of Trelegy royalties for sales of the drug from and after 2029 outside of the U.S. and 2031 in the U.S.“Our decision to retain future Trelegy royalties and potential milestones in the 2022 transaction reflected our confidence in the product's enduring value and commitment to maximize the value of the royalty interest for our shareholders,” Winningham explained, adding that its GSK agreement “further reflects this strategy.” With Trelegy off its hands, the company is turning its full attention to Viatris-partnered nebulized bronchodilator Yupelri for COPD, which it has a 35% sales stake in that came out to $15.4 million in first-quarter earnings for Theravance. The GSK cash will also be used to continue to develop symptomatic neurogenic orthostatic hypotension prospect ampreloxetine, which is currently being evaluated in a phase 3 trial.Theravance is still rebuilding after major setbacks in 2021, when a series of three failed trials left it to cut 75% of its staff, about 270 employees. As it stands, its revenue comes entirely from Yupelri and remaining Trelogy payments from Royalty.

Phase 3License out/inClinical Trial Termination

100 Deals associated with Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	R03AL08	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Asthma	Canada	GlaxoSmithKline, Inc.	30 May 2018
Bronchitis, Chronic	Canada	GlaxoSmithKline, Inc.	04 Apr 2018
Pulmonary Disease, Chronic Obstructive	United States	GlaxoSmithKline Intellectual Property Development Ltd.	18 Sep 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute asthma	Phase 3	United States	GSK Plc	24 Apr 2023
Acute asthma	Phase 3	Argentina	GSK Plc	24 Apr 2023
Acute asthma	Phase 3	Australia	GSK Plc	24 Apr 2023
Acute asthma	Phase 3	New Zealand	GSK Plc	24 Apr 2023
Cardiovascular Diseases	Phase 3	United States	Glaxo Group Ltd.	25 Jan 2012
Cardiovascular Diseases	Phase 3	United States	GlaxoSmithKline (China) Investment Co., Ltd.	25 Jan 2012
Cardiovascular Diseases	Phase 3	Japan	GlaxoSmithKline (China) Investment Co., Ltd.	25 Jan 2012
Cardiovascular Diseases	Phase 3	Japan	Glaxo Group Ltd.	25 Jan 2012
Cardiovascular Diseases	Phase 3	Argentina	GlaxoSmithKline (China) Investment Co., Ltd.	25 Jan 2012
Cardiovascular Diseases	Phase 3	Argentina	Glaxo Group Ltd.	25 Jan 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04937387 (CTgov)	Phase 3	Asthma	359	Fluticasone Furoate [FF]+Vilanterol [VI] (Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug)	gvwamimvcl(invfoxyggs) = gahqeghzvw ryuyjmkfdc (wdwoisgwyp, 0.0321) View more	-	11 Aug 2025
				Fluticasone Furoate [FF]+Vilanterol [VI]+Umeclidinium [UMEC] (Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug)	gvwamimvcl(invfoxyggs) = tzwbmmmmqb ryuyjmkfdc (wdwoisgwyp, 0.0316) View more
ATS2025	Phase 3	Pulmonary Disease, Chronic Obstructive St George's Respiratory Questionnaire (SGRQ)-C questions 1 (cough)	-	Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)	olqifxhqcj(rkpymykoyl) = ffnblcgxta mphrdejnjs (uebpiifbyd )	Positive	16 May 2025
				Budesonide/Formoterol (BUD/FOR)	olqifxhqcj(rkpymykoyl) = bncudfigic mphrdejnjs (uebpiifbyd )
NCT04923347 (CTgov)	Phase 4	Pulmonary Disease, Chronic Obstructive	229	fluticasone furoate+vilanterol+umeclidinium	qlruaiqrgc = odrrfwzsqz xqrdyveale (fgmkuxkckv, dynodctslr - ymaswvicdc) View more	-	24 Mar 2025
NCT05535972 (CTgov)	Phase 4	Pulmonary Disease, Chronic Obstructive	463	fluticasone furoate+vilanterol+Trelegy+umeclidinium	xtmhjdlvmv(vwpjmzoncp) = fzzftwhxat rnallemmul (yxbgqsqunt, 5.49) View more	-	04 Nov 2024
NCT02924688 (CAPTAIN, ATS2024)	Phase 3	Asthma Maintenance	-	FF/UMEC/VI 100/62.5/25mcg	usduguegox(ncyaxroedf) = dsiumpzaye lphwdpllse (gwgawsfvis )	-	19 May 2024
				FF/UMEC/VI 200/62.5/25mcg	usduguegox(ncyaxroedf) = ahiihweshz lphwdpllse (gwgawsfvis )
ATS2024	Not Applicable	Pulmonary Disease, Chronic Obstructive \| Asthma	-	FF/UMEC/VI-100	rkueqsognz(ryydlagvvw) = immtmoytpt ukxoupjipg (kyquxosqgb ) View more	-	19 May 2024
				FF/UMEC/VI-200	rkueqsognz(ryydlagvvw) = ltghfkrpwh ukxoupjipg (kyquxosqgb ) View more
ATS2024	Not Applicable	Pulmonary Disease, Chronic Obstructive	-	Prompt initiation of FF/UMEC/VI	zroppfhhhh(gctoxtyrlp) = nnkqryvjlf otvjtrvilz (pygqbnudbi ) View more	Positive	19 May 2024
				Delayed initiation of FF/UMEC/VI	zroppfhhhh(gctoxtyrlp) = xawujmrmbh otvjtrvilz (pygqbnudbi ) View more
ATS2024	Not Applicable	Pulmonary Disease, Chronic Obstructive	-	Fluticasone Furoate/Umeclidinium/Vilanterol	qeiwtcvnao(zgbeevdjhr) = lvrjgzqrop jrshkgkxqz (hvnzlubgwn )	-	19 May 2024
				Budesonide/Formoterol	qeiwtcvnao(zgbeevdjhr) = bdmryidgrz jrshkgkxqz (hvnzlubgwn )
NCT04651777 (ETHA, CTgov)	Phase 3	Asthma	31	FF/UMEC/VI	qiritwpgei(nldvnpypxl) = pimoffrdxk jrgzgbwzmz (crdtzbbrcd, 12) View more	-	29 Mar 2024
AAAAI2024	Not Applicable	Asthma	-	Fluticasone Furoate/Umeclidinium/Vilanterol-100	lebslgorkj(hslvmprpfg) = agswydatqg wttvajblib (cexkmicbjf ) View more	-	23 Feb 2024
				Fluticasone Furoate/Umeclidinium/Vilanterol-200	lebslgorkj(hslvmprpfg) = yxyjgsjzit wttvajblib (cexkmicbjf ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis